Paul Aliu, PharmD, MRPharmS, MBA
Head of Global Governance, Chief Medical Office
Novartis Pharmaceuticals
Holly Fernandez Lynch, JD, MBE
John Russell Dickson, MD Presidential Assistant Professor of Medical Ethics and Assistant Professor of Law
University of Pennsylvania
Gwen Petersen
Patient Advocate
Abstract: Despite several missteps, the US response to COVID-19 has been characterized by remarkable, all-hands-on-deck science and policy efforts. These approaches have been justified by the overwhelming global impact of the public health emergency, yet for patients with serious unmet medical needs, they seem to offer a glimpse of what should be possible for their own diseases. Patients with ALS, families of children facing rare pediatric cancers, and many others have begun to ask, “Why isn't the FDA prioritizing such early access to unapproved treatments for the diseases likely to kill us or our loved ones, especially if they are more deadly than Covid-19?” In other words: “Where's our Operation Warp Speed?” This panel will compare traditional responses to diseases with unmet needs with those taken to Covid-19.
Presented by the NYU Grossman School of Medicine Division of Medical Ethics Working Group on Compassionate Use and Preapproval Access
Location and Address
Online